NEW YORK (GenomeWeb) – Proove Biosciences announced today that it has acquired Algynomics, a research-stage pain diagnostics company.

Terms of the deal were not disclosed.

Algynomics's platform and patient cohorts provide prospective data to identify individuals at increased risk for chronic pain, Proove said. Such research can be used to target pain prevention efforts, enhance patient stratification in clinical trials to identify treatment responders, produce more sensitive criteria for trial enrollment, and develop algorithms to tailor treatment for pain.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.